Showing 1441-1450 of 4802 results for "".
Evolving Perspectives: The Dermatology M&A Market in Today’s Environment
https://practicaldermatology.com/topics/practice-management/evolving-perspectives-the-dermatology-ma-market-in-todays-environment/23945/Halfway through 2023: The trends and emerging insights in the dermatology and aesthetics industries.The Women's Dermatologic Society Takes Manhattan
https://practicaldermatology.com/topics/practice-management/the-womens-dermatologic-society-takes-manhattan/20579/WDS leaders educate the media on at-home beauty devices, pigment disorders, and more.“Skin May Be Deep, But Dermatologists Are Superficial…”
https://practicaldermatology.com/topics/general-topics/skin-may-be-deep-but-dermatologists-are-superficial/21254/Resident Satisfaction; Plantar Warts Update
https://practicaldermatology.com/youngmd-connect/resident-resource-center/resident-satisfaction-plantar-warts-update/21126/Should You Hire a Scribe?
https://practicaldermatology.com/topics/practice-management/should-you-hire-a-scribe/23923/What to consider before bringing a scribe into your practice and the benefits of doing so.New in My Practice: Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-devices-2/23929/New in My Practice: SkinMedica’s Even & Correct
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-skinmedicas-even-correct/23955/Hyperpigmentation Treatment Pearls and More
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/hyperpigmentation-treatment-pearls-and-more/20161/Corey Hartman, MD shares his approach to treating periorbital hyperpigmentation in darker skin types, including using fillers to replace volume, give lift, and replace loss of bony structures and fat pads. Dr. Hartman also discusses the benefits of Cynosure’s PicoSure device to correct hyperpigmentaDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PUpdates on AD Therapeutics
https://practicaldermatology.com/topics/atopic-dermatitis/updates-on-ad-therapeutics/19760/It's a "super-exciting" time in the world of atopic dermatitis because of a number of new developments happening very rapidly, shares Peter Lio, MD. Recent approvals and additional indications for treatments like dupilumab and crisaborole in pediatric populations have been welcome additions. And the